Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402)
Sign Up to like & getrecommendations! Published in 2018 at "Oncology"
DOI: 10.1159/000486624
Abstract: Background: Regorafenib is an oral multikinase inhibitor with a proven survival benefit for metastatic colorectal cancer patients. The KSCC1402/HGCSG1402 study investigated the prophylactic effect of oral dexamethasone (DEX) on regorafenib-related fatigue and/or malaise. Patients and… read more here.
Keywords: fatigue malaise; group; regorafenib related; related fatigue ... See more keywords
Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.10094
Abstract: 10094Background: KSCC1402/HGCSG1402 is a phase II, randomized, double-blind, placebo (PLC)-controlled study evaluating the prophylactic effects of oral dexamethasone (DEX) on regorafenib-related fa... read more here.
Keywords: kscc1402 hgcsg1402; regorafenib related; double blind;